A U.S. Senate panel last week approved a bill that directs the Department of Veterans Affairs (VA) to conduct research into cannabis as a treatment for chronic pain and post-traumatic stress disorder (PTSD). The bipartisan legislation, which was introduced by Montana Democrat Senator Jon Tester on February 9 and co-sponsored by Senator Dan Sullivan, a Republican from Alaska, was approved by the Senate Veterans Affairs Committee with a vote during a closed-door session on Thursday.
Under the bill (S. 326), the VA would be tasked with conducting a large-scale observational study that evaluates the safety and efficacy of cannabis as a treatment for PTSD and chronic pain. An identical bill (H.R. 1003) sponsored by California Democratic Representative Lou Correa is also pending in the House of Representatives, with Republican Representative Jack Bergman signed on as a co-sponsor.
The observational study would explore the positive and negative health outcomes of cannabis use by veterans, including whether using marijuana reduces the use of alcohol or opiates. The study would also investigate other aspects of medicinal cannabis use, including sleep quality, pain intensity, agitation, and overall quality of life. Once the study is complete, the legislation requires the VA to report back to Congress on the results and the feasibility of conducting clinical trials.
Senate Veterans Affairs committee chair Jon Tester, a Democrat from Montana, said in a statement when he introduced the bill earlier this month that the legislation will give military veterans new choices to manage their health care.
“Our nation’s veterans deserve options when it comes to treating the wounds of war, which is why VA needs to have a better understanding of how medicinal cannabis plays a role in their healing,” Tester said. “Our bipartisan bill ensures VA is listening to the growing number of veterans who find critical relief from alternative treatments like medicinal cannabis, while working to empower veterans in making safe and informed decisions about their health.”
A New Milestone In Cannabis Policy Reform
Lawmakers in both chambers of Congress have introduced similar legislation in previous years, including a bill that was approved by the House Veterans Affairs Committee two years ago. Thursday’s approval by the Senate panel, however, is the first advancement of a veterans cannabis research bill in the upper chamber of Congress.
“Many of our brave men and women in uniform suffer from unseen wounds of war as a result of their sacrifices on behalf of our country, wounds that often manifest in post-traumatic stress,” Sullivan said in a statement when the bill was introduced. “We owe it to these courageous service members, past and present, to explore and better understand new remedies for these mental health challenges that are safe and effective, treatments that could give our suffering veterans hope.”
Tester’s bill also directs the VA to assess the ability of the agency to coordinate FDA-approved clinical trials into the safety and effectiveness of cannabis and cannabis extracts for health care among veterans. If approved by the VA, the clinical trials would provide study participants with cannabis products from federally licensed producers and compare the results with a control group.
Thursday’s approval of S. 326 by the Senate Veterans Affairs Committee is being hailed by medical marijuana and cannabis policy reform advocates as a significant step forward in the movement to end the prohibition of weed in the United States.
“I’m heartened to see the U.S. Senate take an essential step forward on what should be a priority we all agree on — taking care of our country’s veterans and providing them with alternative treatments for things like PTSD and chronic pain management,” Steven Jung, a U.S. Army veteran and the chief operations officer of vaporizer manufacturer PAX, said in an email to High Times. “Veterans are in crisis and at much greater risk of suicide than the national average, and it’s time we take action now.”
With medical cannabis legal in the majority of states in the country, the number of adults who have turned to the treatment for chronic pain has likewise increased.
The researchers contacted 1,724 adults, 96% of whom (1,661) completed the full survey.
Among them, “31.0%…of adults with chronic pain reported having ever used cannabis to manage their pain; 25.9%… reported using cannabis to manage their chronic pain in the past 12 months, and 23.2%… reported using cannabis in the past 30 days,” the researchers wrote.
The researchers said that “more than half of adults who used cannabis to manage their chronic pain reported that use of cannabis led them to decrease use of prescription opioid, prescription nonopioid, and over-the-counter pain medications, and less than 1% reported that use of cannabis increased their use of these medications.”
“Fewer than half of respondents reported that cannabis use changed their use of nonpharmacologic pain treatments,” they wrote in their findings. “Among adults with chronic pain in this study, 38.7% reported that their used of cannabis led to decreased use of physical therapy (5.9% reported it led to increased use), 19.1% reported it led to decreased use of meditation (23.7% reported it led to increased use), and 26.0% reported it led to decreased used of cognitive behavioral therapy (17.1% reported it led to increased use).”
Thirty-seven states in the U.S. have medical cannabis programs on the books. Among adults living with chronic pain in those states, “3 in 10 persons reported using cannabis to manage their pain,” according to the new study.
“Most persons who used cannabis as a treatment for chronic pain reported substituting cannabis in place of other pain medications including prescription opioids. The high degree of substitution of cannabis with both opioid and nonopioid treatment emphasizes the importance of research to clarify the effectiveness and potential adverse consequences of cannabis for chronic pain,” the researchers wrote. “Our results suggest that state cannabis laws have enabled access to cannabis as an analgesic treatment despite knowledge gaps in use as a medical treatment for pain. Limitations include the possibility of sampling and self-reporting biases, although NORC AmeriSpeak uses best-practice probability-based recruitment, and changes in pain treatment from other factors (eg, forced opioid tapering).”
The findings serve as another source of encouragement for advocates who hope patients continue to seek treatment from cannabis, rather than highly addictive prescription drugs.
The CDC says that the “rise in opioid overdose deaths can be outlined in three distinct waves.”
“The first wave began with increased prescribing of opioids in the 1990s, with overdose deaths involving prescription opioids (natural and semi-synthetic opioids and methadone) increasing since at least 1999,” according to the CDC. “The second wave began in 2010, with rapid increases in overdose deaths involving heroin. The third wave began in 2013, with significant increases in overdose deaths involving synthetic opioids, particularly those involving illicitly manufactured fentanyl. The market for illicitly manufactured fentanyl continues to change, and it can be found in combination with heroin, counterfeit pills, and cocaine.”
Mark Bicket, one of the authors of the new study who also serves as assistant professor in the Department of Anesthesiology and co-director of the Michigan Opioid Prescribing Engagement Network, said that the “fact that patients report substituting cannabis for pain medications so much underscores the need for research on the benefits and risk of using cannabis for chronic pain.”
Despite some recent headlines that cannabis pain relief is a placebo, a new study has found that 1/3 of people with chronic pain choose cannabis for relief. The study, published in JAMA Network Open, surveyed over 1,700 adults. Over half of them said cannabis allows them to decrease the use of prescription opioids and other pain medications. Beyond pain relief, the adults surveyed also said cannabis helped them with mental health issues that usually accompany chronic pain. One of the […]
With the opioid epidemic underway, the question of how to reverse direction is on everyone’s mind. Governments are succumbing to pressure; passing decriminalization measures, and opening safe use sites, but none of this attacks the problem. Though a ketamine answer exists, its been all but ignored in terms of the general public, which is 100% unaware of this. And now, a new pain pill is under research, but is still completely untested. What is BnOCPA, and how does it measure up?
There’s a new non-opioid painkiller under research called BnOCPA, and it might be a very much needed alternative to the current and awful opioid situation. We’re a cannabis and psychedelics news site which specializes in breaking news and ongoing stories in these industries, and beyond. We provide theCannadelics Weekly Newsletter for readers to stay updated, as well as obtain access to an array of product promotions on vapes and other smoking devices, edibles, and cannabinoid compounds including the super-popular Delta 8 & HHC. Head to our ‘best of’ lists for more info, and buy yourself some awesome new swag.
Why it matters
There are a ton of pharma products on the market, and plenty for pain. Aside from opioids, which dominate the scene, we’re pretty used to our Tylenol, and NSAIDS like aspirin, and ibuprofen. For the entirety of my life, the process has been to pop a pill for pretty much anything. Skin your knee? Take a pill. Got a headache? Take a pill. That time of the month? Take a pill. It’s a wonder anyone knows what pain feels like anymore.
Prior to our new-age pharma world, if you hurt yourself, you just had to deal with it. Or use the natural medicine version, which, let’s be honest, isn’t the worst. All those opioids that are causing so much problem, are all based on compounds from the poppy plant, and those compounds have existed, and been implored in local medicine traditions, for as long as people have lived in organized communities.
In light of the massive addiction and death numbers of late, it’s a wonder people are more willing to pop the pill, than simply tough it out. After all, it was standard once to have children without an epidural, or to cut off diseased limbs without an anesthetic. While I’m not saying progress isn’t good, I am saying that in this case, it came with a cost. Obviously, the logic of ‘we didn’t need it before, so we don’t need it now’ isn’t the best, but it’s not worthless either. It mainly fails because if nothing else, we live way longer than humans used to, meaning an increase in pain related issues from aging, and overall more years to experience accidents and mishaps.
BnOCPA vs opioids
As of right now, that issue of trying to get away from the pain, is manifesting in the form of overdose deaths from opioids. According to preliminary data released by the CDC in May of this year, 2021 had approximately 107,622 overdose deaths. And while we don’t know the exact breakdown of causes, we know that of 2020’s 93,000 overdose deaths, that over 68,000 were opioid related. That’s a lot of people dying from drugs prescribed by a doctor. How prevalent are these prescriptions? As of a 2021 analysis, in 2019, 22.1% of all US adults with chronic pain, obtained an opioid prescription within the last three months of the question. In 2017, it accounted for 191 million prescriptions.
BnOCPA – What is this stuff?
Right now, when it comes to dealing with chronic and extreme pain, opioids are the go-to prescription medication, though this has shown to be a very bad idea in terms of addiction rates to the medications, and accompanied overdoses. Opioids are synthetically made compounds based on the poppy plant. When compounds are taken directly from the plant, they’re called opiates, but when made synthetically, but based on the compounds of the plant, they’re opioids. Opioids include drugs like fentanyl and the main component of Oxycontin, oxycodone.
Opioids assert their action by attaching to opioid receptors in the nervous system, and gastrointestinal tract. The three main opioid receptor classes are mu, kappa, and delta – μ, κ, δ, though there are 17 of these receptors currently known about. They operate as heavy pain relievers, as well as anesthetics; with prescription uses for things like diarrhea and cough suppression as well.
BnOCPA is a newly made synthetic compound that recently came to global attention with the results of a recent investigation. BnOCPA, or benzyloxy-cyclopentyladenosine, is a G-protein-coupled receptor agonist (GPCRs). Research into this compound was carried out by a group of investigators based out of the University of Warwick’s School of Life Sciences (in conjunction with University of Bern, University of Cambridge, Coventry University, Monash University, and different industrial organizations). According to their study, Selective activation of Gαob by an adenosine A1 receptor agonist elicits analgesia without cardiorespiratory depression, this compound:
“…is a potent and powerful analgesic but does not cause sedation, bradycardia, hypotension or respiratory depression.” This occurs because of “BnOCPA’s unique and exquisitely selective activation of Gob among the six Gαi/o subtypes, and in the absence of β-arrestin recruitment.”
They go on to explain that the compound “demonstrates a highly-specific Gα-selective activation of the native A1R,” which “sheds new light on GPCR signalling,” and which “reveals new possibilities for the development of novel therapeutics based on the far-reaching concept of selective Gα agonism.” This is different from other adenosine receptors, like the A1 receptors, which though showing potential in this realm, are weighed down by side effects of sedation and cardiorespiratory depression.
BnOCPA as opioid alternative
How does BnOCPA differ from opioids?
When it comes to extreme, chronic pain, medications like Advil and Tylenol can’t help much, and we know this because enough time has gone by to understand where their abilities end. Different kinds of pain medication vary in how much coverage they can realistically provide. When looking at other options to opioids, this has to be considered, because the medication must be strong enough to solve the problem, while not including the negative side effects that lead to overdose and death.
Opioid receptors are also G-protein-coupled receptors, meaning opioids attach to the same kinds of receptors as this new compound, BnOCPA. But that doesn’t mean the two different compounds create the same response, and there’s a particular reason why. G-proteins cause a lot of different effects, and drugs like opioids inadvertently set off several kinds of them because they’re not selective in where they bind. The pain-relieving effects are therefore included with unwanted effects (or side effects), as well.
BnOCPA functions a bit differently in that its way more selective about where it binds, thus only triggering one kind of G-protein. This ability for selection can minimize the amount of side effects that come with the medication, hence the aforementioned ability for pain control, without causing sedation or respiratory depression. As sedation and respiratory depression lead to overdose when too much of a drug creating these actions is taken, the ability to get around this means a possible way to treat pain, without worrying about a death toll.
According to lead researcher Dr. Mark Wall, “The selectivity and potency of BnOCPA make it truly unique and we hope that with further research it will be possible to generate potent painkillers to help patients cope with chronic pain.”
This finding came unexpectedly. Says Professor Bruno Frenguelli of the research team, “This is a fantastic example of serendipity in science. We had no expectations that BnOCPA would behave any differently from other molecules in its class, but the more we looked into BnOCPA we discovered properties that had never been seen before, and which may open up new areas of medicinal chemistry.”
What do we actually know beyond these statements? Unfortunately, nothing. While it sounds super awesome thus far, it should be remembered that this is one study on a compound that’s never been used before. It must be researched further, and undergo a slew of testing, including human trials, before anything further is known for sure. We don’t know what kind of pain it can handle, how safe it is for long term use, or if there is an addiction potential. Right now, the only thing we know is that an untested compound was created, that might provide an alternative to opioids.
Why not ketamine?
Ketamine as opioid alternative
I harp on this a lot, but for good reason. Yeah, there’s a massive issue right now with opioids killing people. So massive that to cope with it, some locations are giving up and decriminalizing the drugs, or instituting programs like safe use sites to try to minimize deaths. However, despite all measures, overdose rates are very clearly rising, indicating that nothing is getting better, and that even bigger problems should be expected in the future.
So, yeah, its great that alternatives are getting some attention, but let’s be honest for a second, BnOCPA is new, and untested. Maybe it provides a better option, but we won’t know that for quite some time, because long term data requires a lot of time, or its not long term data. We can only know those answers by people using it through time, or studies that follow long-term use. Meaning since we have this problem right now, if there is another method that is tested, and safe, and which might provide extra benefits, like long-lasting relief between administration sessions, it should be used. Immediately. Right?
Well, we have a drug that is comparable to opioids in terms of chronic and acute pain management. One which, like BnOCPA, has that ability for pain relief without causing sedation or cardiac depression, and which actually has the capacity to work for months after administration (find me an opioid that lasts the amount of time its supposed to, let alone longer). And yet here we are talking about a new and untested compound, instead. Maybe BnOCPA does work, is safe, and isn’t addictive, but you know what we already know works, is safe, and isn’t addictive? Ketamine.
The real question when a story like this comes out, isn’t whether BnOCPA can provide a better option to opioids, but why we aren’t talking about the already tested and safe medications we actually have access to now. Sure, its great to create and research new compounds, but when it comes to an answer to the opioid epidemic, and one that is accessible immediately, BnOCPA isn’t it. However, ketamine is.
Conclusion
The pharma world is a confusing place, and its not always clear why one thing is pushed and another is not. While BnOCPA might be a new contender in the opioid battle, if we really want to win this war, we need to use all the artillery in our arsenal. And right now, a new and untested compound doesn’t compare to one that’s been around since the 60’s, with accumulated use and safety information since that time.
Welcome to the site! Thanks for joining us today at Cannadelics.com, your favorite stop for comprehensive and independent coverage of the growing cannabis and psychedelics fields. Join us frequently to stay informed on important stories, and subscribe to the Cannadelics Weekly Newsletter, so you’re always first to know what’s going on.
While recreational and medical legalization is sweeping the country, a recent study revealed that enrollment in medical-only programs quadrupled between 2016 and 2020.
The study on U.S. medical cannabis trends also looked at qualifying conditions listed by patients, and revealed that enrollment increased in states with only medical cannabis. States that also offer recreational cannabis use declined or stayed the same. Overall, chronic pain was the most common condition reported on applications.
This research project, titled “U.S. Trends in Registration for Medical Cannabis and Reasons for Use From 2016 to 2020” and published with Annals of Internal Medicine, was spearheaded by lead author Kevin Boehnke, an expert on chronic pain at University of Michigan. His goal with the study was to look specifically at medical enrollment, not cannabis use overall, to determine cannabis trends.
During his work on the study, he asked himself, “How many people are using cannabis for pain? Why are people actually using [medical cannabis]?”
With these questions in mind, Boehnke began a years-long look into what this enrollment and cannabis use looked like, using public data available from reports and state websites, meeting notes, state officials, and documents he got access to thanks to the Freedom of Information Act. He was specifically interested in what the trends looked like as they shifted under the changing medical and recreational laws across the country.
He also published another study on the issue in 2019, “Qualifying Conditions Of Medical Cannabis License Holders In The United States,” in HealthAffairs, but this new study has an even broader scope with more access to data.
“These changing state policies have dramatic effects on how many people might be using cannabis for medical purposes or how they might be able to do so,” Boehnke says regarding the study, according to STAT News.
STAT News also spoke to Byron Adinoff, a drug addiction researcher and president of Doctors for Cannabis Regulation, about the study. He was happy about the results, and hopes to see more studies that highlight how key medical cannabis treatment can be. While he admits that he, like many doctors, was hesitant for a long time about prescribing medical cannabis, his views have changed as information like this becomes available.
“I didn’t really buy into it, but, you know, after you talk to several hundred people who have benefited from it, you start to think maybe there’s something to it,” he says. “Hopefully it will get organized medicine and physicians individually to pay increasing attention to this issue,” he added.
Another substantial piece of data was how much patient enrollment increased in Oklahoma. In that state, there was more than a significant jump to report. According to the study, one in 10 residents of the state are medical cannabis patients, a record high number. This could be because the state does not require specific medical conditions to qualify for a medical card. They can get medical cannabis for any conditions a doctor deems reasonable.
All other medical states in the U.S. at this time have a list of qualifying conditions for what patients are eligible for when it comes to medical cannabis. Chronic pain is allowed in most states, so it’s no surprise that it’s at the top of the list for what patients are medicating for.
STAT News also spoke to Silvia Martins, an epidemiologist at Columbia University specializing in substance use, who hopes this study can lead to more confidence in how cannabis can treat chronic pain.
“Even for chronic pain, we need more evidence, but for other types of conditions, we need even more evidence,” she says regarding the information in the study.
After all the delays, obfuscations and denials, the British are finally taking the next obvious step toward a better understanding of the medical efficacy of cannabinoids. Namely, a highly limited medical cannabis trial dubbed Canpain focusing on chronic pain has just been announced. However, so far, despite reports to the contrary in the media, including The London Times, medical regulators have still not formally authorized a wide-spread study of cannabis and pain management.
While a small trial is a good first step, the question remains why this has taken so long to even get going, let alone why the project is so limited.
Canpain is not the first cannabis experiment in the country and is far from the largest. That distinction goes to Project TWENTY21, organized by a non-profit research organization called Drug Science.
However, Canpain would be, upon proper launch, the first government backed trial which could also lead to patients finally being prescribed medical cannabis via the National Health Service (or NHS).
Its success remains in doubt, however, particularly given what is happening elsewhere in Europe right now. This includes Germany, the largest reimbursed medical cannabis market in the EU, where public health insurers are increasingly turning down applications for medical cannabis authorization on the basis of “just” chronic pain.
What Is Actually About to Happen
The initial “feasibility study” will be conducted by a private cannabis clinic, LVL Health, which will first enroll 100 patients as a first step of the larger experiment (which has not yet even been approved by the NHS). Canpain aims to enroll up to 5,000 adult patients who will receive cartridges with unprocessed cannabis flower on a daily basis for at least one year.
This will not be completely free. Patients will have to pay about $300 per month to receive capsules embedded into vaping devices.
What Is New?
The big news here is that NICE — the National Institute for Health and Care Excellence — will, once the feasibility study is reviewed, approved, and launched, examine the data to determine if the clinical evidence justifies the prescription of cannabis for chronic pain.
In the past, NICE has specifically denied that there was any evidence supporting the use of cannabis to manage chronic pain. According to government data, one in three Britons suffers from this condition—defined as that which creates severe discomfort for more than three months.
By definition, the new Canpain trial in the offing is also admitting that their first limited medical efforts will also exclude most of the chronic pain patients in the country.
In the US, in sharp contrast, the number one reason for medical cannabis use is in fact, chronic pain.
The Slow, Shameful Pace of Cannabis Reform In the UK
Like everywhere else, cannabis reform of even the medical kind has been vigorously fought by British government authorities and agencies, even after medicinal cannabis was technically legalized here in 2018 and a larger medical trial, albeit still limited, was launched in Germany in 2017. Even fewer people have actually gotten prescriptions in the UK than Germany since then via the NHS. Even worse, thanks to the NICE intervention, chronic pain patients were explicitly excluded from receiving reimbursed care post 2018, even if they had managed to obtain such permission previously. Only 18 cannabis prescriptions were subsequently written through the NHS (for whatever reason) and only 259 private prescriptions were issued in 2019.
ProjectTWENTY21 launched in August 2020 with the goal of providing lower cost cannabis to registered patients and studying the same with the goal of providing a large-scale clinical trial that also helped patients obtain cannabis at a lower cost than is available through private medical care. Many cannabis cultivators signed up, at a considerable cost, to be able to provide lower cost cannabis via this trial. About 20,000 patients have subsequently become part of this trial which has now expanded to Australia.
It is not clear why this data has so far been ignored by government authorities.
In the meantime, both further medical and recreational reform debates continue to rage in the UK as the mayor of London, Sadiq Khan, has announced that he will launch a recreational cannabis decriminalization trial in certain parts of London.
Beyond this effort, no British national authority has taken either medical or recreational cannabis reform seriously.
As a result, British, just like other European patients are still mostly left out in the cold and stuck between outrageous monthly costs via private health care, the black market, or going untreated (which is obviously not a viable option for most patients).
The Criminalization of Legitimate Patients Continues
For all the police press releases about tackling drug crime, there is no effort currently underway to track the fates of legitimate patients who are routinely arrested and prosecuted under federal narcotics laws which they are still subject to when their applications for medical treatment are denied (for whatever reason). All of these patients must go somewhere to find another source to obtain cannabis and, when turned down by insurers, this almost always means that such individuals have to turn to illicit sources because they cannot afford private care.
In Germany right now, insurers are routinely turning down 40% of patient applications — and for a variety of specious reasons including supposed lack of clinical evidence — even when presented with the most recent data, refusing to process complicated forms that even doctors get “wrong” or even denying patients reimbursed care because their healthcare provider sent in forms later than insurance company imposed deadlines. The only reliable way to obtain legitimate medical cannabis in Germany right now is to have enough money to obtain private healthcare or sue one’s public insurer.
Despite all the protests, and data, one thing is clear. There is a long, hard fight still ahead before the cannabis plant is normalized, anywhere.
How many more people have to face criminal charges or even die before that happens?
*** PRESS RELEASE *** San Francisco, CA – Herzliya, Israel, August 17, 2021 – Cannformatics, an early-stage biotechnology startup focused on the identification and application of saliva-based Cannabis-Responsive TM biomarkers and Cannabotech, a biomedical company developing medical solutions based on botanical combinations of cannabis extracts and functional mushrooms, today announced that Cannabotech has commissioned Cannformatics to conduct a study to evaluate the effects of Cannabotech’s Cannabo-Nerve combination on human patients suffering from chronic neuropathic pain. This study will also compare “MycoCann NeuroPain” to other leading off-the-shelf medical cannabis pain relievers that are currently being sold in the state of CA.
“We are honored that Cannabotech chose Cannformatics to scientifically evaluate the impact of “MycoCann NeuroPain”. Pharmacometabolomic data in combination with study participant pain assessments are unique in their ability to provide insights into a product’s physiological mechanism of action and ability to manage chronic pain,” said Cannformatics CEO and Cofounder, Dr. Itzhak Kurek. “This is an exciting opportunity to support Cannabotech in bringing new hope to patients suffering with chronic neuropathic pain and deepen our understanding of pain related Cannabis-Responsive biomarkers.”
The study will be conducted under the supervision of an FDA regulated Institutional Review Board (IRB) in conjunction with Cannformatics’ Advisory Board members Dr. Donald Abrams and Dr. Bonni Goldstein. Subject to receiving IRB approval, Cannformatics will begin recruiting participants for the study. People interested in participating the study may sign up for study updates HERE.
Elchanan Shaked, CEO and Chairman of Cannabotech, said: “For the past two-years Cannabotech has built a rigorous scientific pipeline for the development of cannabis- and mushroom-based products. The unique formulation that will be tested combines an exact composition of 13 cannabinoids and terpenes with mushroom extracts for the purpose of reducing chronic neuropathic pain without THC-related psychoactive effects. Cannformatics’ technology will provide novel insights obtained in a real-world setting, adding an important layer to the high- quality scientific evidence necessary to gain the support of the medical community ahead of a planned launching of “MycoCann NeuroPain” in the second half of 2022.”
About Cannformatics, Inc: Cannformatics is an early-stage biotechnology startup focused on the personalization of medical cannabis treatment through the identification and application of Cannabis- Responsive biomarkers found in saliva. The company’s mission is to deliver recommendations for predictable and repeatable science-based medical cannabis treatment to improve health and quality of life. The company is now pursuing identifying Cannabis-ResponsiveTM biomarkers related to autism spectrum disorder in children. Cannformatics is headquartered in San Francisco, CA.
About Cannabotech, Inc: Cannabotech is an Israeli biomedical company developing botanical solutions for preventive & integrative medicine. These solutions are based on combinations of active ingredients from the cannabis plant and medicinal mushrooms focusing on two main systems in the human body: the endocannabinoid (ECS) system and the immune system. The Company’s goal is to develop products that can be integrated into existing oncology treatment protocols. Cannabotech is developing a series of eight formulas designed to help patients suffering from five cancer types (Pancreatic, Colorectal, Breast, Lung & Prostate), and minimize chemotherapy-induced chemotherapy-induced neuropathic pain (CINP) and chemotherapy-induced nausea and vomiting (CINV). Cannabotech is headquartered in Herzliya, Israel.
Medical Marijuana is a scheduled drug and there are different federal as well as state regulations governing the use of medical marijuana. Medical marijuana is a promising treatment for quite a few conditions and research is still being conducted. We will focus on the four most proven use cases. Medical marijuana can be obtained in […]
